A blood cancer patient’s long road to diagnosis

Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers, including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), that affect blood cell production in the bone marrow. These blood cancers may result in debilitating symptoms that can burden daily life. Unfortunately, patients often struggle to have their needs met when confronting their illness. The good news is, people all over the world living with MPNs, their caregivers and clinicians are working together to understand the unique physical, emotional and economic challenges that the MPN …

/by

Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients

Novartis today announced that following an interim analysis of data from the CIRRUS-1 study, a decision has been taken to discontinue the trial. 

  • The analysis indicated that CFZ533 (iscalimab)-based treatment is less efficacious compared to tacrolimus-based treatment in the prevention of organ rejection in patients receiving a kidney transplant. Both CFZ533 and tacrolimus were used in combination with other immunosuppressive therapies (induction therapy, mycophenolate and corticosteroids).
  • Study of CFZ533 in liver transplant continues, as do studies exploring CFZ533 as a …
/by

Novartis presents new findings at ERS reinforcing the efficacy of Enerzair® Breezhaler®, highlighting its digital companion, as well as showcasing commitment to low carbon footprint asthma solutions

  • Novartis will present 12 abstracts at the European Respiratory Society (ERS) International Congress 2021 for Enerzair® Breezhaler® (IND/GLY/MF*) and Atectura® Breezhaler® (IND/MF**) — for patients whose asthma is uncontrolled with LABA/ICS^ and ICS, respectively1,2
  • Data from post hoc analyses of the Phase III PLATINUM program (including IRIDIUM and ARGON studies) further establish efficacy of Enerzair …
/by